Keywords: genzyme, hylastan, falls, short, oa, trial, biotechnology

Genzyme's hylastan falls short in OA trial

Article | 16 July 2007

Print This

US biotechnology giant Genzyme says that its developmental drug hylastan failed to reduce pain to a greater extent than steroids ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in